Overview

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

Status:
Completed
Trial end date:
2002-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Octreotide may help doxorubicin kill more cancer cells by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of octreotide and doxorubicin in treating patients who have advanced cancer.
Phase:
Phase 1
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Cancer Institute (NCI)
Treatments:
Doxorubicin
Liposomal doxorubicin
Octreotide